Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

AMG 510 in NSCLC

print
PRINT
insite
SEARCH

This trial is investigating the safety and efficacy of AMG 510 – an agent targeting KRAS – in patients with advanced solid tumors harboring a KRAS G12C mutation.

Phase I trial results

AMG 510 has demonstrated promising efficacy and tolerability in previously treated patients with locally advanced or metastatic KRAS-mutated non-small-cell lung cancer.

Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the trial and the next steps for the research (5:34):

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019:

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT